We are developing the next generation of cancer treatment.
The long term goal of the MUNIN (HK) Limited (“MUNIN”) is the Discovery of Patentable New Medicines through Molecular Genetics Research, from which the company expects to generate profits through the sale of novel proprietary therapeutic products and/or revenue from third parties who license, produce and sell such patent-protected products.
The current key technology platform (protected by 6 issued US and corresponding foreign patents) is the use of the CCN (Cyr61, CTGF, and Nov) family of proteins and their modifiers as novel therapeutics in angiogenesis (the growth of new blood vessels).
Our company’s research and development team has concluded that the suppression of the Cyr61 clinical target is significantly superior to the targeting of other angiogenic growth-factor(s)/receptor(s) (such as VEGF, Her2, FGF, PDGF) in the development of a broad-spectrum anti-angiogenesis anti-cancer therapeutic. This assessment is based on Cyr61’s functional role as the key tumor-secreted angiogenesis inducing molecule employed by multiple tumor angiogenesis signaling pathways to initiate angiogenesis.